Sara Nadworny
Ariadne Diagnostics (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer therapeutics and mechanisms, PI3K/AKT/mTOR signaling in cancer, Lung Cancer Research Studies, HER2/EGFR in Cancer Research
Most-Cited Works
- → The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models(2016)321 cited
- → Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer(2021)190 cited
- → Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models(2016)29 cited
- → Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non–small cell lung cancer(2022)22 cited
- → Abstract 781: The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models(2015)10 cited
- → Abstract B167: Preclinical characterization of THE-349, a mutant-selective, CNS-active, fourth-generation EGFR inhibitor to overcome T790M- and C797S-mediated resistance in NSCLC(2023)2 cited
- → Abstract B209: The CD37-targeting ADC IMGN529 combines the potent anticancer activity of K7153A antibody with efficient maytansinoid delivery.(2011)1 cited
- → Data from The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models(2023)
- → Data from Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer(2023)
- → Abstract 3342: Discovery of potent and selective next-generation EGFR inhibitors with activity against single, double, and triple mutant EGFR variants including T790M and C797S(2022)